Xencor, Inc. (XNCR)

In the past six months, Xencor's stock has trended up by 55.01%, reaching $11.53 as of February 4, 2026. Insider transactions occurred in January 2026. The stock experienced fluctuations in December and November 2025. Xencor reported a net loss attributable to Xencor of $6.0 million for Q3 2025, an improvement from the previous year, driven by unrealized gains. Xencor reported a net loss of $48.4 million for Q1 2025, with revenue up due to non-cash royalty and milestone revenue.

As a clinical-stage biopharmaceutical company, Xencor's revenue is primarily derived from collaboration agreements, product licensing, technology licensing, and royalties, making traditional demand seasonality less applicable. The company's financial performance is driven by clinical trial progress, regulatory approvals, achievement of milestones, and overall market trends in the biotechnology and pharmaceutical sectors.

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics for cancer and autoimmune diseases, utilizing its proprietary XmAb® technology platform to enhance antibody functionality. The company's pipeline includes various product candidates like XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, XmAb657, Ultomiris, Monjuvi, Sotrovimab, and Xaluritamig, with revenue generated through collaboration agreements, product licensing, and technology licensing, including royalties from marketed products.

Xencor, Inc. is headquartered in Pasadena, California, with an office in San Diego, California. Its geographic footprint extends internationally through partnerships and product approvals, such as Ultomiris in the EU and Japan, and Sotrovimab in over 30 countries. The company is eligible for royalties on worldwide net sales for products developed with its XmAb Fc domains.

Xencor's brand reputation has been positively influenced by the advancement of pipeline candidates, including plans to begin a first-in-human study of their TL1A x IL23p19 bispecific antibody. Positive clinical data from Phase 1 studies of XmAb541 and XmAb819, as well as partner progress with Amgen's xaluritamig entering Phase 3, have contributed positively. The issuance of a U.S. patent covering its Xtend™ Fc domain and the significant reduction in net loss for Q3 2025 have also enhanced the company's reputation.

Xencor, Inc. has 406 institutional owners and shareholders holding a total of 102,423,742 shares. Major institutional owners include BlackRock, Inc., Primecap Management Co/ca/, Vanguard Group Inc, and others. The company's co-founders, Dr. Bassil Dahiyat and Dr. Stephen Mayo, also retain ownership stakes.